CUV — Clinuvel Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- AU$720.83m
- AU$547.45m
- AU$82.23m
- 96
- 30
- 27
- 53
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 19.7 | ||
| PEG Ratio (f) | 2.37 | ||
| EPS Growth (f) | 9.08% | ||
| Dividend Yield (f) | 0.51% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.03 | ||
| Price to Tang. Book | 4.04 | ||
| Price to Free Cashflow | 19.84 | ||
| Price to Sales | 8.26 | ||
| EV to EBITDA | 10.89 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 27.04% | ||
| Return on Equity | 18.97% | ||
| Operating Margin | 56.46% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 31.61 | 33.13 | 48.32 | 66.17 | 82.23 | 89.42 | 98.54 | 26.14% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +37.1 | -14.82 | +60.57 | -17.24 | +46.79 | +12.6 | +8.33 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Clinuvel Pharmaceuticals Limited is a global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. The Company is engaged in managing and expanding commercial distribution of its lead drug candidate, SCENESSE, in Europe, the United States, Israel, and Australia for the treatment of a rare, genetic metabolic disorder, erythropoietic protoporphyria (EPP). The Company’s pipeline includes PRENUMBRA, NEURACTHEL, CUV9900, and Parvysmelanotide (VLRX001). PRENUMBRA is a liquid (non-solid) injectable formulation of afamelanotide designed to provide a flexible dose of afamelanotide, a synthetic analogue of natural a-melanocyte stimulating hormone. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH), for neurological, endocrinological and degenerative disorders.
Directors
- Willem Blijdorp NEC (69)
- Philippe Wolgen CEO
- Darren Keamy CFO
- Dennis Wright CSO
- Karen Agersborg NID
- Jeffrey Rosenfeld NID
- Brenda Shanahan NID
- Susan Smith NID
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 14th, 1999
- Public Since
- February 13th, 2001
- No. of Shareholders
- 5,672
- No. of Employees
- 16
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 50,127,270
- Address
- Level 22, 535 Bourke Street, MELBOURNE, 3000
- Web
- https://www.clinuvel.com/
- Phone
- +61 396604900
- Auditors
- Grant Thornton Audit Pty Ltd
Upcoming Events for CUV
Similar to CUV
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
Auscann group
Australian Stock Exchange - SEATS
FAQ
What is the Clinuvel Pharmaceuticals share price?
As of Today at 19:05 UTC, shares in Clinuvel Pharmaceuticals are trading at AU$14.38. This share price information is delayed by 15 minutes.
How has the Clinuvel Pharmaceuticals share price performed this year?
Shares in Clinuvel Pharmaceuticals last closed at AU$14.38 and the price had moved by -29.2% over the past 365 days. In terms of relative price strength the Clinuvel Pharmaceuticals share price has underperformed the ASX All Ordinaries Index by -32.28% over the past year.
What are the analyst and broker recommendations for Clinuvel Pharmaceuticals?
The overall consensus recommendation for Clinuvel Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Clinuvel Pharmaceuticals dividend yield?
The Clinuvel Pharmaceuticals dividend yield is 0.35% based on the trailing twelve month period.
Does Clinuvel Pharmaceuticals pay a dividend?
Last year, Clinuvel Pharmaceuticals paid a total dividend of AU$0.05, and it currently has a trailing dividend yield of 0.35%. We do not have any data on when Clinuvel Pharmaceuticals is to next pay dividends.
When does Clinuvel Pharmaceuticals next pay dividends?
We do not have data on when Clinuvel Pharmaceuticals is to next pay dividends. The historic dividend yield on Clinuvel Pharmaceuticals shares is currently 0.35%.
How do I buy Clinuvel Pharmaceuticals shares?
To buy shares in Clinuvel Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Clinuvel Pharmaceuticals?
As of the previous close price of AU$14.38, shares in Clinuvel Pharmaceuticals had a market capitalisation of AU$720.83m.
Where are Clinuvel Pharmaceuticals shares listed?
Here are the trading details for Clinuvel Pharmaceuticals:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: CUV
What kind of share is Clinuvel Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Clinuvel Pharmaceuticals is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Clinuvel Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Clinuvel Pharmaceuticals is AU$26.41. That is 83.67% above the last closing price of AU$14.38.
Analysts covering Clinuvel Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of AU$0.68 for the next financial year.
What is the trend in the Clinuvel Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Clinuvel Pharmaceuticals. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -17.22%.
As of the last closing price of AU$14.38, shares in Clinuvel Pharmaceuticals were trading -11.89% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Clinuvel Pharmaceuticals PE Ratio?
The Clinuvel Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 19.7. The shares last closed at AU$14.38.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Clinuvel Pharmaceuticals?
Clinuvel Pharmaceuticals' management team is headed by:
- Willem Blijdorp - NEC
- Philippe Wolgen - CEO
- Darren Keamy - CFO
- Dennis Wright - CSO
- Karen Agersborg - NID
- Jeffrey Rosenfeld - NID
- Brenda Shanahan - NID
- Susan Smith - NID